Results 21 to 30 of about 12,661 (240)
Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways [PDF]
Background Biomarker discovery is a challenging task due to the massive search space. Quantum computing and quantum Artificial Intelligence (quantum AI) can be used to address the computational problem of biomarker discovery from genetic data.
Phuong-Nam Nguyen
semanticscholar +1 more source
Several studies have demonstrated that the genetic polymorphisms in the genes encoding immune regulatory molecules, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and CD28, play a fundamental role in susceptibility to rheumatoid arthritis (RA)
Mohammad Javad Mousavi +6 more
doaj +1 more source
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous success treating B-cell malignancies, however some patients fail to respond due to poor autologous T cell fitness.
Sangya Agarwal +19 more
semanticscholar +1 more source
CTLA4-Ig protects tacrolimus-induced oxidative stress via inhibiting the AKT/FOXO3 signaling pathway in rats [PDF]
Background/Aims Although the conversion from tacrolimus (TAC) to cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (CTLA4-Ig) is effective in reducing TAC-induced nephrotoxicity, it remains unclear whether CTLA4-Ig has a direct effect on TAC ...
Long Jin +5 more
doaj +1 more source
CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis
Hui and colleagues show that CTLA4 acts in cis to deplete T cell–associated B7 ligands and that ipilimumab treatment inhibits this process to promote T cell autostimulation. This suggests a novel aspect of CTLA4 function with therapeutic implications.
Xiaozheng Xu +8 more
semanticscholar +1 more source
BACKGROUND Lipopolysaccharide-responsive beige-like anchor (LRBA) deficiency (LRBA-/-) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) insufficiency (CTLA4+/-) are mechanistically overlapped diseases presenting with recurrent infections and ...
Nigar Taghizade +54 more
semanticscholar +1 more source
PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
Despite the unprecedented success in using immune checkpoint inhibitors in the treatment of lung cancer, melanoma, hypermutable tumors of various localization, etc., a significant proportion of patients receiving these drugs do not respond to treatment ...
G. A. Janus +11 more
doaj +1 more source
The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting the search for immune modulating agents that
K. Fjæstad +9 more
semanticscholar +1 more source
LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively kill ...
Takahiro Yamazaki +10 more
doaj +1 more source
CTLA4-CD28 gene fusion has been reported to occur in diverse types of T cell lymphoma. The fusion event is expected to convert inhibitory signals to activating signals and promote proliferation and potentially transformation of T cells.
Gyu Jin Lee +5 more
doaj +1 more source

